OligoG-pivotal-CF
  • Project
  • Challenge
  • Partners
  • Status
  • News
  • Resources
  • Menu

Klicken Sie auf die entsprechende Schaltfläche unten, um ein Video des Inhalationsvorgangs zu sehen

Klicken Sie hier (Kind)
Klicken Sie hier (Erwachsener)

Klicken Sie auf die Schaltfläche unten, um die Gebrauchsanweisung anzuzeigen (und drucken Sie sie gegebenenfalls in Ihrem Browser aus)

Gebrauchsanweisung

About the project

OligoG-pivotal-CF is a multinational clinical project to test the orphan drug OligoG CF-5/20 (OligoG) in a pivotal phase 2b clinical trial for the treatment of cystic fibrosis (CF). The project is funded by the H2020-SC1-2017-Two-Stage-RTD, topic SC1-PM-08-2017, and represents a new therapy for the rare disease cystic fibrosis (CF). The study drug OligoG CF-5/20 (OligoG) has received an EU Orphan Drug Medicinal Product Designation in 2007 and an FDA Orphan Drug Designation February 2016, both for the treatment of cystic fibrosis.

Contact information

For further details of the project please contact anne.graver@algipharma.com

Cookie Policy

OligoGpivotalCF logo

Funding

EU flag - OligoGpivotalCF

This project has received funding from the European Union’s Horizon 2020 research and innovation programme part “Health, demographic change and well-being” (call H2020-SC1-2016-2017) under grant agreement No 755234.

© AlgiPharma / Web & design by Havdur Design
  • Project
  • Challenge
  • Partners
  • Status
  • News
  • Resources
Scroll to top